Five takeaways on progress altering the Parkinson’s therapeutic landscape, from day two of The Michael J. Fox Foundation’s ...

Neurology residents explore Parkinson's care, research advances and career opportunities at the 2026 MDS-PAS Movement Disorders School.

Each year, The Michael J. Fox Foundation (MJFF) hosts the Parkinson’s Disease Therapeutics Conference (PDTC), the world’s only scientific meeting devoted exclusively to Parkinson’s drug development.

This small event features an interactive program with remarks on the state of Parkinson’s research and progress toward a cure. You’ll learn about our landmark Parkinson’s Progression Markers ...

Managing Parkinson’s medications can be a complex task no matter where you or your loved one are in your journey with PD. When is it best to start or adjust medication? How much should you take? How ...

Dr. Shill received her medical degree from the University of Arizona, College of Medicine. She completed her internship at St. Joseph’s Hospital and Medical Center in internal medicine. Dr. Shill ...

The U.S. Food and Drug Administration (FDA) has approved a new, long-acting oral formulation for the treatment of Parkinson's disease. Developed by Amneal Pharmaceuticals, Crexont aims to offer ...

Levodopa was approved to treat Parkinson’s disease (PD) over 50 years ago and today it remains the “gold standard” of treatment. As levodopa is the most effective medication to ease Parkinson’s ...

As part of The Michael J. Fox Foundation’s goal to support the development of new and better Parkinson’s treatments, we are regularly assessing and tracking the drug development pipeline. Five areas ...

The U.S. Food and Drug Administration has approved a treatment that uses focused ultrasound on both sides of the brain (in two procedures, months apart) for the management of Parkinson’s-related ...

Editor’s note (March 21, 2024): This blog describes a skin test that detects the biology of Parkinson’s and related diseases, and, as such, is a valuable research tool. On March 20, 2024, researchers ...

The U.S. Food and Drug Administration (FDA) has approved tavapadon, a once-daily oral medication for the treatment of motor symptoms of Parkinson’s disease. Tavapadon, which will be sold under the ...